CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...

CheckMate 816: what does the data tell us?Подробнее

Neoadjuvant nivolumab + chemo continues to provide long-term clinical benefit for NSCLC patientsПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022Подробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IOПодробнее

Surgical outcomes from the Phase III CheckMate 816 trialПодробнее